Federico Garrido

List of Publications by Year
in descending order

126 papers	9,343 citations	34105 52 h-index	42399 92 g-index
130 all docs	130 docs citations	130 times ranked	9226 citing authors

#	Article	IF	Citations
1	Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Trends in Immunology, 1997, 18, 89-95.	7.5	708
2	The urgent need to recover MHC class I in cancers for effective immunotherapy. Current Opinion in Immunology, 2016, 39, 44-51.	5.5	464
3	Natural history of HLA expression during tumour development. Trends in Immunology, 1993, 14, 491-499.	7.5	432
4	MHC class I antigens, immune surveillance, and tumor immune escape. Journal of Cellular Physiology, 2003, 195, 346-355.	4.1	422
5	Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. Cancer Research, 2013, 73, 3499-3510.	0.9	277
6	MHC antigens and tumor escape from immune surveillance. Advances in Cancer Research, 2001, 83, 117-158.	5.0	263
7	The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunology, Immunotherapy, 2004, 53, 904-10.	4.2	239
8	HLA class I antigen abnormalities and immune escape by malignant cells. Seminars in Cancer Biology, 2002, 12, 3-13.	9.6	233
9	â€œHardâ€•and â€œsoftâ€•lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. International Journal of Cancer, 2010, 127, 249-256.	5.1	232
10	Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2?-deoxycytidine treatment. International Journal of Cancer, 2001, 94, 243-251.	5.1	225
11	Analysis of HLA-E expression in human tumors. Immunogenetics, 2003, 54, 767-775.	2.4	143
12	Further evidence for derepression of Hâ€“2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. Nature, 1976, 261, 705-707.	27.8	140
13	The HLA crossroad in tumor immunology. Human Immunology, 2000, 61, 65-73.	2.4	129
14	Immune escape of cancer cells with beta2â€microglobulin loss over the course of metastatic melanoma. International Journal of Cancer, 2014, 134, 102-113.	5.1	129
15	Hâ€“2-like specificities of foreign haplotypes appearing on a mouse sarcoma after vaccinia virus infection. Nature, 1976, 259, 228-230.	27.8	128
16	MHC Class I Antigens and Immune Surveillance in Transformed Cells. International Review of Cytology, 2007, 256, 139-189.	6.2	128
17	High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Human Immunology, 1996, 50, 127-134.	2.4	126
18	Hla Class I Antigens in Human Tumors. Advances in Cancer Research, 1995, 67, 155-195.	5.0	121

#	Article	IF	Citations
19	Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics, 2008, 60, 439-447.	2.4	119
20	Role of Altered Expression of HLA Class I Molecules in Cancer Progression. Advances in Experimental Medicine and Biology, 2007, 601, 123-131.	1.6	117
21	Coordinated downregulation of the antigen presentation machinery and HLA class I/Î²2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. International Journal of Cancer, 2005, 113, 605-610.	5.1	116
22	Rejection versus escape: the tumor MHC dilemma. Cancer Immunology, Immunotherapy, 2017, 66, 259-271.	4.2	115
23	Tumour immunology: MHC antigens and malignancy. Nature, 1986, 322, 502-503.	27.8	106
24	Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunology, Immunotherapy, 2002, 51, 389-396.	4.2	105
25	Implication of the Î²2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunology, Immunotherapy, 2012, 61, 1359-1371.	4.2	105
26	Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. , 1999, 83, 91-97.		104
27	Cancer immune escape: <scp>MHC</scp> expression in primary tumours versus metastases. Immunology, 2019, 158, 255-266.	4.4	102
28	The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses. Current Opinion in Immunology, 2018, 51, 123-132.	5.5	99
29	Analysis of HLA expression in human tumor tissues. Cancer Immunology, Immunotherapy, 2003, 52, 1-9.	4.2	98
30	Complete loss of HLA class I antigen expression on melanoma cells: A result of successive mutational events. International Journal of Cancer, 2003, 103, 759-767.	5.1	88
31	Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunology, Immunotherapy, 2005, 54, 400-406.	4.2	88
32	Chapter 7 IFN Inducibility of Major Histocompatibility Antigens in Tumors. Advances in Cancer Research, 2008, 101, 249-276.	5.0	84
33	High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Human Immunology, 2007, 68, 698-704.	2.4	83
34	The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible â€œhardâ€• lesions. Cancer Immunology, Immunotherapy, 2010, 59, 1601-1606.	4.2	82
35	MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. International Journal of Cancer, 2003, 106, 521-527.	5.1	79
36	Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. International Journal of Cancer, 2001, 91, 109-119.	5.1	78

#	Article	IF	Citations
37	HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunology, Immunotherapy, 2007, 56, 709-717.	4.2	78
38	Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics, 2004, 56, 244-53.	2.4	77
39	Frequent loss of heterozygosity in the Î²2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics, 2011, 63, 65-71.	2.4	75
40	Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferonâ€mediated rejection genes. International Journal of Cancer, 2012, 131, 387-395.	5.1	75
41	The absence of HLA class I expression in nonâ€small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration. International Journal of Cancer, 2017, 140, 888-899.	5.1	75
42	Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer, 2007, 7, 34.	2.6	74
43	MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis, 2012, 33, 687-693.	2.8	69
44	Metastases in Immune-Mediated Dormancy: A New Opportunity for Targeting Cancer. Cancer Research, 2014, 74, 6750-6757.	0.9	66
45	HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. Oncotarget, 2018, 9, 4120-4133.	1.8	66
46	Expression of HLA G in human tumors is not a frequent event. , 1999, 81, 512-518.		65
47	Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunology, Immunotherapy, 2005, 54, 858-866.	4.2	62
48	The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture. Vaccines, 2017, 5, 7.	4.4	62
49	Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 2008, 8, 382.	2.6	59
50	Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Human Immunology, 2000, 61, 1001-1012.	2.4	58
51	LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas. Immunogenetics, 2006, 58, 503-510.	2.4	56
52	Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunology, Immunotherapy, 2008, 57, 1727-1733.	4.2	56
53	HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy. Cellular and Molecular Immunology, 2021, 18, 556-565.	10.5	55
54	HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunology, Immunotherapy, 2009, 58, 1507-1515.	4.2	53

#	Article	IF	Citations
55	T Lymphocytes Restrain Spontaneous Metastases in Permanent Dormancy. Cancer Research, 2014, 74, 1958-1968.	0.9	53
56	Bacillus Calmetteâ€Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class Iâ€deficient tumor cells. International Journal of Cancer, 2011, 129, 839-846.	5.1	52
57	Can the HLA phenotype be used as a prognostic factor in breast carcinomas?. International Journal of Cancer, 1991, 47, 146-154.	5.1	50
58	Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunology, Immunotherapy, 2007, 56, 88-94.	4.2	50
59	MHC/HLA Class I Loss in Cancer Cells. Advances in Experimental Medicine and Biology, 2019, 1151, 15-78.	1.6	50
60	Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach. International Journal of Molecular Sciences, 2015, 16, 13610-13632.	4.1	47
61	HLA class I expression and HPVâ€16 sequences in premalignant and malignant lesions of the cervix. Tissue Antigens, 1993, 41, 65-71.	1.0	46
62	Methylated CpG points identified withinMAGE-1 promoter are involved in gene repression. , 1996, 68, 464-470.		46
63	Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells. Human Immunology, 2009, 70, 854-857.	2.4	45
64	High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Human Immunology, 2000, 61, 499-506.	2.4	43
65	Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunology, Immunotherapy, 2008, 57, 719-729.	4.2	43
66	NK sensitivity and lung clearance of MHC-class-I-deficient cells within a heterogeneous fibrosarcoma. International Journal of Cancer, 1989, 44, 675-680.	5.1	40
67	Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer. Human Immunology, 2012, 73, 668-672.	2.4	40
68	The tumour suppressor <i>Fhit</i> positively regulates MHC class I expression on cancer cells. Journal of Pathology, 2012, 227, 367-379.	4.5	36
69	HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15. Immunogenetics, 2018, 70, 647-659.	2.4	36
70	Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. International Journal of Cancer, 2016, 138, 271-280.	5.1	35
71	Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance. Cancer Immunology, Immunotherapy, 2016, 65, 47-59.	4.2	35
72	Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clinical and Experimental Metastasis, 1989, 7, 213-226.	3.3	34

#	Article	IF	Citations
73	High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunology, Immunotherapy, 2005, 54, 141-148.	4.2	33
74	Analysis of HLAâ€"ABC locus-specific transcription in normal tissues. Immunogenetics, 2010, 62, 711-719.	2.4	33
75	Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression. Cancer Immunology, Immunotherapy, 2019, 68, 2015-2027.	4.2	33
76	Immunotherapy eradicates metastases with reversible defects in MHC class I expression. Cancer Immunology, Immunotherapy, 2011, 60, 1257-1268.	4.2	32
77	In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele. , 1998, 75, 317-323.		31
78	Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Seminars in Cancer Biology, 2002, 12, 15-24.	9.6	31
79	HLA Class-I Expression and Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2019, 1151, 79-90.	1.6	31
80	A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells. Immunogenetics, 2000, 51, 1047-1052.	2.4	30
81	A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line. Immunogenetics, 2001, 53, 606-610.	2.4	29
82	Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape. Cancer Immunology, Immunotherapy, 2012, 61, 803-816.	4.2	29
83	Heterogeneity of MHC-class-I antigens in clones of methylcholanthrene-induced tumors. Implications for local growth and metastasis. International Journal of Cancer, 1991, 47, 73-81.	5.1	27
84	Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas. International Journal of Cancer, 2004, 109, 636-638.	5.1	27
85	Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Human Immunology, 2010, 71, 309-313.	2.4	27
86	Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab. Frontiers in Pharmacology, 2017, 8, 595.	3.5	27
87	High frequency of HLA-B44 allelic losses in human solid tumors. Human Immunology, 2003, 64, 941-950.	2.4	26
88	Targetless T cells in cancer immunotherapy. , 2016, 4, 23.		26
89	Molecular analysis of MHC-class-I alterations in human tumor cell lines. International Journal of Cancer, 1991, 47, 123-130.	5.1	25
90	HLA molecules in basal cell carcinoma of the skin. Immunobiology, 1992, 185, 440-452.	1.9	25

#	Article	IF	Citations
91	Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunology, Immunotherapy, 2010, 59, 13-26.	4.2	25
92	MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy. Frontiers in Immunology, 2018, 9, 102.	4.8	25
93	Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line. Cancer Immunology, Immunotherapy, 2001, 50, 191-198.	4.2	23
94	Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors. International Journal of Cancer, 2005, 113, 611-618.	5.1	22
95	Upmodulation by estrogen of HLA class I expression in breast tumor cell lines. Immunogenetics, 1994, 39, 161-7.	2.4	19
96	Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. Cancer Immunology, Immunotherapy, 2011, 60, 869-882.	4.2	19
97	HLA Class I and II Expression in Rhabdomyosarcomas. Immunobiology, 1991, 182, 440-448.	1.9	18
98	Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients. Oncotarget, 2018, 9, 36929-36944.	1.8	18
99	K-ras mutations (codon 12) are not involved in down-regulation of mhc class-i genes in colon carcinomas. International Journal of Cancer, 1990, 46, 426-431.	5.1	17
100	Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients. Journal of Microbiology, Immunology and Infection, 2022, 55, 421-427.	3.1	15
101	Late pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: a case report. Journal of Medical Case Reports, 2008, 2, 111.	0.8	14
102	A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Human Immunology, 2009, 70, 60-64.	2.4	14
103	Generation and control of metastasis in experimental tumor systems; inhibition of experimental metastases by a tilorone analogue. International Journal of Cancer, 1993, 54, 518-523.	5.1	13
104	HLA and cancer. Tissue Antigens, 1996, 47, 361-363.	1.0	13
105	Looking for HLA-G expression in human tumours. Journal of Reproductive Immunology, 1999, 43, 263-273.	1.9	13
106	Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response. International Journal of Cancer, 2007, 121, 2023-2030.	5.1	12
107	Restoration of MHC-I on Tumor Cells by Fhit Transfection Promotes Immune Rejection and Acts as an Individualized Immunotherapeutic Vaccine. Cancers, 2020, 12, 1563.	3.7	12
108	MHC heterogeneity and response of metastases to immunotherapy. Cancer and Metastasis Reviews, 2021, 40, 501-517.	5.9	12

#	Article	IF	Citations
109	Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer. Cancers, 2021, 13, 5046.	3.7	12
110	Class II HLA Antigen Expression in Familial Polyposis Coli is Related to the Degree of Dysplasia. Immunobiology, 1990, 180, 138-148.	1.9	11
111	A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer. Annals of Surgical Oncology, 2019, 26, 2631-2639.	1.5	11
112	Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes. International Journal of Molecular Sciences, 2021, 22, 7248.	4.1	11
113	Multiple mechanisms are responsible for the alteration in the expression of HLA class I antigens in melanoma. International Journal of Cancer, 2003, 105, 432-433.	5.1	9
114	Expression of Î±-tropomyosin during cardiac development in the chick embryo. The Anatomical Record, 1992, 234, 301-309.	1.8	6
115	Differential MAGE-1 Gene Expression in Two Variants of an Erythroleukemic Cell Line (K562). Immunobiology, 1995, 194, 449-456.	1.9	5
116	Oxidative stress induces the expression of the major histocompatibility complex in murine tumor cells. Free Radical Research, 2001, 35, 119-128.	3.3	4
117	HLA Class-II Expression in Human Tumors. Advances in Experimental Medicine and Biology, 2019, 1151, 91-95.	1.6	4
118	HLA Class I Expression, Tumor Escape and Cancer Progression. Current Cancer Therapy Reviews, 2008, 4, 105-110.	0.3	3
119	Introduction. Advances in Experimental Medicine and Biology, 2019, 1151, 1-14.	1.6	3
120	Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. International Journal of Cancer, 1999, 83, 91-97.	5.1	3
121	The Biological Implications of the Abnormal Expression of Histocompatibility Antigens on Murine and Human Tumors. , 1987, , 623-639.		3
122	A novel preclinical murine model of immune-mediated metastatic dormancy. OncoImmunology, 2014, 3, e29258.	4.6	2
123	In vivo and in vitro generation of a new altered HLA phenotype in melanomaâ€tumourâ€cell variants expressing a single HLAâ€classâ€I allele. International Journal of Cancer, 1998, 75, 317-323.	5.1	1
124	â€œHardâ€•and â€œsoftâ€•lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. , 2010, 127, 249.		1
125	MHC Class I Antigens and the Tumor Microenvironment. , 2013, , 253-286.		0
126	CRC: A Darwinian model of cellular immunoselection. , 2022, , 529-541.		0